摘要
目的:观察骨痹舒片治疗膝骨关节炎(KOA)的临床疗效,探讨膝骨关节炎早、中期运用骨痹舒片的疗效并阐述其作用机理,以能更好地推广防治膝骨关节炎的最佳方案。方法:采用随机、平行对照、多中心临床治疗观察方法将120例中医辨证为肝肾亏虚证的膝骨关节炎患者分为骨痹舒片治疗组(A组,58例)、抗骨质增生胶囊治疗组(B组,34例)、健膝丸治疗组(C组,28例)。3组分别采用骨痹舒片、抗骨质增生胶囊、健膝丸治疗3个月。观察记录各组治疗前后临床症状、膝关节功能活动及不良反应情况,并检测各组患者治疗前后血沉(ESR)、C反应蛋白(CRP)指标,进行统计分析比较。结果:经临床治疗3个月后,3组患者关节晨僵时间、关节压痛、肿胀、疼痛、关节功能活动及ESR、CRP与治疗前比较,均有明显改善(P<0.01),且A组改善明显优于C、B组(P<0.01);3组显效率比较,A组改善明显优于C、B组(P<0.05)。结论:骨痹舒片治疗膝骨关节炎临床效果良好,无明显的不良反应。
Objective： To observe the clinical efficacy of Gubishu Tablet on the treatment of knee osteoarthritis （KOA）, explore the efficacy of it on KOA at the early and mid stages and describe its mechanism of action, in order to better spread the best solution to the prevention of KOA. Methods： With randomized, parallel control, and multi-center clinical observation methods, 120 KOA patients due to liver-kidney deficiency were divided into the Gubishu Tablet-treated Group （Group A, 58 cases）, the Anti-hyperostosis Capsule-treated Group （Group B, 34 cases） and the Jianxi Pill-treated Group （Group C, 28 cases）. All patients were treated for three months. Before and after treatment, observed and recorded the clinical symptoms, the knee function activity, and adverse reactions, and detected the erythrocyte sedimentation rate （ESR） and the C-reactive protein （CRP） of patients in each group, statistically analyzing and comparing the results. Results： After three months＇ treatment, significant improvement was shown in the time of morning stiffness in joints, joint tenderness, swelling, pain, joint functional activities, ESR, and CRP among the three groups （P 〈 0. 01）, with Group A better than Group B and Group C （P 〈 0. 01）. As for the markedly effective rate, Group A was better than Group B and Group C （P 〈 0. 05）. Conclusions： Gubishu Tablet showed favorable effects in the treatment of KOA with no obvious adverse reaction.
出处
《风湿病与关节炎》
2012年第3期24-27,共4页
Rheumatism and Arthritis
关键词
膝骨关节炎
骨痹舒片
抗骨增生胶囊
健膝丸
临床研究
knee osteoarthritis
gubishu tablet
anti-hyperostosis capsule
jianxi pill
clinical study
